Roo Study on Mom and Baby Well-Being

September 27, 2023 updated by: Alice Graham, Oregon Health and Science University

A Targeted Approach to Examine the Influence of Maternal Psychological Stress on Newborn Brain Outcomes

This study employs a randomized controlled trial of an established intervention, Mindfulness Based Cognitive Therapy (MBCT) adapted for pregnancy, to examine effects on various aspects of maternal psychological stress during pregnancy (magnitude and trajectories of stress) and offspring brain systems integral to healthy and maladaptive emotion regulation. This study considers other potential influences on maternal stress and psychiatric symptomatology, and infant behavior and brain development. The study population is pregnant women aged 21-45, and their infants.

Study Overview

Detailed Description

The study will involve an online screen of potentially eligible pregnant women. If women are eligible after the online screen, they will be invited in for an in-person assessment, including cognitive testing and a diagnostic interview, to further determine eligibility. After the assessment, they will be informed of their eligibility status and, if applicable, randomized to a Mindfulness Based Cognitive Therapy (MBCT) group involving an 8-session group-based intervention or to treatment as usual (TAU) during pregnancy followed by one mindfulness psychoeducation session postpartum. Eligible participants will then be invited in for a study visit during which they will give blood, urine, and saliva samples. Participants in the MBCT group will complete questionnaires prior to the 1st group session, after the 4th session, and after the 8th/final session. Participants in the TAU group will complete the same questionnaires at equivalent time points. All participants will come in for an in-person session at 34 weeks GA, during which they will complete questionnaires, a brief clinical interview and provide blood, urine, and saliva samples again. Participants will then come in with their infant for the infant MRI scan within one month of giving birth. Study staff will collect a hair and saliva sample from the infant at this time. Participants will have a remote visit at 6 weeks postpartum, during which time they will complete questionnaires and a clinical interview. At 6 months postpartum, participants will return for their final visit, during which they will complete questionnaires and a clinical interview. Mothers and infants will also provide a hair sample at this time. Some visits will be adapted as needed to accommodate institutional requirements with regard to restrictions due to COVID-19.

Study Type

Interventional

Enrollment (Actual)

140

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Oregon
      • Portland, Oregon, United States, 97239
        • Oregon Health and Science University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

3 days to 45 years (Child, Adult)

Accepts Healthy Volunteers

Yes

Description

Pregnant Women/ Mothers:

Inclusion and exclusion criteria for pregnant women/ mothers will be determined by a combination of the initial screen and intake assessment.

Inclusion criteria include:

  1. be 21-45 years old
  2. be a female who is currently pregnant (8-22 weeks GA at screening)
  3. fluently speak English
  4. be available and physically able to attend group scheduled meetings
  5. have a single gestation, and
  6. have a history of an internalizing psychiatric disorder.

Exclusion criteria include:

  1. Major neurological or medical condition (e.g., diabetes, MS),
  2. IQ <80
  3. maternal use of psychotropic medications, insulin, or any other medications that might impact the central nervous system (at the time of enrollment)
  4. current diagnosis of substance use disorder, illicit drug use or nicotine use
  5. diagnosis of autism, developmental disorder involving intellectual disability or a psychotic disorder
  6. current major depressive episode, eating disorder or manic episode
  7. current active suicidality and/or homicidally, or interpersonal violence
  8. prior history of engaging in mindfulness-based psychotherapeutic interventions (e.g., MBCT, MBSR, DBT (mindfulness module))
  9. pregnancy-specific medical conditions or complications including placental abnormality or other conditions requiring bed rest
  10. known congenital, genetic, or neurologic disorder of the fetus (e.g., Down syndrome, fragile X)
  11. uncorrectable vision or hearing impairments (including color blindness)

Infants:

Inclusion for infants to participate in MRI scan include:

  1. being between 37 and 50 weeks gestational age (GA) equivalent at time of 1st scan*
  2. not meeting any of the exclusion criteria below.

    • We are using GA equivalent rather than postnatal age because infants born pre-term will not be scanned prior to term equivalent (37 weeks GA). Therefore, infants who are born preterm may be older in terms of postnatal age, but will be similar to infants born at term with regard to time since conception. The time since conception is more pertinent to our measures of brain development versus postnatal age.

Exclusion criteria for infants (specifically exclusionary for MRI scan) include:

  1. congenital, genetic, or neurologic disorder (e.g., Down syndrome, fragile X)
  2. major neurologic disorder at birth (e.g., bacterial meningitis, epilepsy)
  3. birth < 30 weeks GA
  4. medical complications following birth requiring ongoing hospitalization.
  5. medical complications or health problems at or following birth, which could make an MRI scan unsafe or uncomfortable

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Mindfulness Based Cognitive Therapy
MBCT adapted for pregnancy includes 8 sequential, weekly 2-hour group sessions co-led by two master's level therapists. Sessions include: 1) introducing new mindfulness skills through in-session practice, 2) reviewing mindfulness practices and troubleshooting barriers to practice, 3) reinforcing mindfulness skills through in-session practice and debriefing, 4) learning about how thoughts influence feelings and behaviors (not all sessions), 5) providing psychoeducational information to support skills, and 6) encouraging the establishment of social support. The intervention is focused on skill development through active engagement in mindfulness practices and exercises to increase awareness of thoughts, feelings and behavior in session, and assignment and review of daily home practices.
See "Mindfulness Based Cognitive Therapy (MBCT) Arm" description
Other Names:
  • Mindfulness Based Cognitive Therapy for Perinatal Depression
No Intervention: Treatment as Usual
All participants will receive routine prenatal care from an identified medical provider, which they have initiated on their own. They will be able to engage in any services recommended by their primary medical provider or that they voluntarily initiate. For ethical reasons, they are not prohibited from engaging in any type of therapeutic, complementary, or medication treatment (after enrollment). The TAU group will be offered a delayed treatment option, after the 6 month follow-up. This will be a 2 hour mindfulness psychoeducation session, offered between 6 and 9 months postpartum. Several core mindfulness concepts included in the full MBCT curriculum will be taught and participants will complete several brief mindfulness activities.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Maternal Psychological Stress
Time Frame: Intake - 34 Weeks GA (T5)
Maternal psychological stress will be a composite of the Perceived Stress Scale (PSS), Beck Anxiety Inventory (BAI), and Pregnancy Distress Questionnaire (PDQ) The magnitude and trajectory of maternal psychological stress will be examined.
Intake - 34 Weeks GA (T5)
Maternal Depression
Time Frame: Intake - 34 Weeks GA (T5)
Maternal depressive symptoms will be measured using the Center for Epidemiologic Studies Depression Scale - Revised (CESD-R). The magnitude and trajectory of maternal psychological stress will be examined.
Intake - 34 Weeks GA (T5)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Blood assay for inflammatory marker IL6
Time Frame: 34 Weeks GA (T5)
Levels of IL6 assayed from maternal blood samples. Difference in magnitude of inflammation between groups at T5 after adjusting for inflammation prior to the intervention.
34 Weeks GA (T5)
Maternal Cortisol
Time Frame: 34 Weeks GA (T5)
The cortisol levels obtained from participant's hair samples to assess cumulative cortisol from pre- to post-intervention.
34 Weeks GA (T5)
Neonatal Resting State fMRI scan
Time Frame: Infant Scan (T6)
MRI scans with neonates will occur during natural sleep. Resting state functional connectivity will be the outcome of interest.
Infant Scan (T6)
Neonatal Structural MRI scan
Time Frame: Infant Scan (T6)
MRI scans with neonates will occur during natural sleep. Neonatal subcortical brain structure volume will be the outcome of interest.
Infant Scan (T6)
Maternal Pregnancy Specific Psychological Stress
Time Frame: Intake - 34 weeks (T5)
The Prenatal Distress Questionnaire (PDQ) is a short measure designed to assess specific worries and concerns related to pregnancy.
Intake - 34 weeks (T5)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Alice Graham, PHD, Oregon Health and Science University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2019

Primary Completion (Actual)

May 24, 2022

Study Completion (Actual)

September 1, 2022

Study Registration Dates

First Submitted

January 9, 2019

First Submitted That Met QC Criteria

January 16, 2019

First Posted (Actual)

January 18, 2019

Study Record Updates

Last Update Posted (Actual)

September 29, 2023

Last Update Submitted That Met QC Criteria

September 27, 2023

Last Verified

September 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • R00MH111805 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

We propose to share individual participant data in accord with the NIMH Data Archive Data Submission Agreement.

IPD Sharing Time Frame

In accord with the NIMH Data Archive Data Submission Agreement policies we will share data on a semi-annual basis beginning 6-months after initiating data collection and through the end of the study.

IPD Sharing Access Criteria

Data will be available through the NIMH Data Archive by following the procedures for Data Use Certification.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pregnancy Related

Clinical Trials on Mindfulness Based Cognitive Therapy

Subscribe